Kraus, J., Kraus, M., Liu, N., Besse, L., Bader, J., Geurink, P. P., . . . Driessen, C. (2015). The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells. Cancer Chemother Pharmacol.
Citação norma ChicagoKraus, Johannes, et al. "The Novel β2-selective Proteasome Inhibitor LU-102 Decreases Phosphorylation of I Kappa B and Induces Highly Synergistic Cytotoxicity in Combination With Ibrutinib in Multiple Myeloma Cells." Cancer Chemother Pharmacol 2015.
Citação norma MLAKraus, Johannes, et al. "The Novel β2-selective Proteasome Inhibitor LU-102 Decreases Phosphorylation of I Kappa B and Induces Highly Synergistic Cytotoxicity in Combination With Ibrutinib in Multiple Myeloma Cells." Cancer Chemother Pharmacol 2015.